Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

SPERO THERAPEUTICS, INC.

(SPRO)
  Report
Delayed Nasdaq  -  04:00 2022-09-23 pm EDT
1.970 USD   -10.45%
09/23GSK and Spero Therapeutics announce exclusive licence agreement for tebipenem HBr, a late-stage antibiotic that may treat complicated urinary tract infections
AQ
09/22ADRs End Mostly Lower; Compagnie de Saint-Gobain Trades Actively
DJ
09/22Evercore ISI Upgrades Spero Therapeutics to Outperform From In-Line
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Spero Therapeutics Shares Take Flight Premarket on GSK Pact

09/22/2022 | 08:53am EDT

By Colin Kellaher


Shares of Spero Therapeutics Inc. nearly doubled in premarket trading Thursday after the clinical-stage biopharmaceutical company agreed to license tebipenem HBr, its late-stage antibiotic asset, to U.K. pharma major GSK PLC in a deal potentially worth hundreds of millions of dollars to Spero.

Under the agreement, Spero will receive an upfront payment of $66 million from GSK, which also will invest $9 million to buy 7.45 million Spero shares at around $1.21 apiece, a 47% premium to Wednesday's closing price of about 82.2 cents for the Cambridge, Mass., company.

Spero said it is also eligible for up to $525 million in future milestone payments, along with royalties on sales.

Spero shares were recently up 92% to $1.58 in premarket trading Thursday.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

09-22-22 0615ET

Stocks mentioned in the article
ChangeLast1st jan.
GSK PLC 1.33% 1313.2 Delayed Quote.-20.10%
SPERO THERAPEUTICS, INC. -10.45% 1.97 Delayed Quote.-87.70%
All news about SPERO THERAPEUTICS, INC.
09/23GSK and Spero Therapeutics announce exclusive licence agreement for tebipenem HBr, a la..
AQ
09/22ADRs End Mostly Lower; Compagnie de Saint-Gobain Trades Actively
DJ
09/22Evercore ISI Upgrades Spero Therapeutics to Outperform From In-Line
MT
09/22SECTOR UPDATE : Health Care Stocks Gain Thursday Afternoon
MT
09/22SECTOR UPDATE : Health Care
MT
09/22Top Midday Gainers
MT
09/22GLOBAL MARKETS LIVE : Veolia, Meta, Amazon, Salesforce, Target...
MS
09/22Fed up!
MS
09/22SECTOR UPDATE : Health Care Stocks Mixed Premarket Thursday
MT
09/22SECTOR UPDATE : Health Care
MT
More news
Analyst Recommendations on SPERO THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 10,8 M - -
Net income 2022 -80,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,82x
Yield 2022 -
Capitalization 69,1 M 69,1 M -
Capi. / Sales 2022 6,37x
Capi. / Sales 2023 18,8x
Nbr of Employees 41
Free-Float 84,2%
Chart SPERO THERAPEUTICS, INC.
Duration : Period :
Spero Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SPERO THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,97 $
Average target price 6,67 $
Spread / Average Target 238%
EPS Revisions
Managers and Directors
Ankit A. Mahadevia President, Chief Executive Officer & Director
Satyavrat Shukla Chief Financial Officer & Treasurer
Milind S. Deshpande Chairman
Thomas R. Parr Chief Scientific Officer
Angela Talley Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
SPERO THERAPEUTICS, INC.-87.70%69
GILEAD SCIENCES, INC.-13.43%78 787
REGENERON PHARMACEUTICALS, INC.10.42%74 550
VERTEX PHARMACEUTICALS29.08%72 693
BIONTECH SE-50.21%31 192
WUXI APPTEC CO., LTD.-41.46%28 154